ArticleJournal of neuroimmunology2025
Greater fatigue, disturbed sleep, persistent memory problems, and reduced CD4
Article in Journal of neuroimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The use ofFrontiers in cell and developmental biology · 2026Review
- Translational Evidence of Immunomodulation by Addictive Drugs: Mechanisms and Therapeutic Targets.Journal of neuroimmunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Methamphetamine (MA) dependence is associated with immunotoxicity and high rates of neuropsychiatric impairments that persist into remission. Although there are currently no FDA-approved pharmacotherapies for MA use disorders, preclinical and clinical studies are beginning to test interventions that directly impact immune signaling. This study was conducted to investigate the relative contribution of immune cell function to the neuropsychiatric sequelae associated with MA dependence and remission. Participants were enrolled into the following study groups: i) control (CTL) group (n = 62): adults with no lifetime history of dependence on any substance other than nicotine or caffeine; and ii) MA group (n = 98) [MA-remission group (n = 55): adults in remission ≥1 month and ≤ 6 months and MA-active group (n = 43): adults actively using MA and meeting criteria for MA dependence]. Participants completed a clinical interview, urine drug analysis, blood sample collection, and questionnaires. Peripheral blood mononuclear cells were analyzed by flow cytometry. Results suggest that early remission from MA dependence is associated with increased fatigue and persistent sleep and prospective and retrospective memory problems, along with reduced B and CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.